Table 1 Demographics of treatment-naïve (A) and pre-treated (B) BC patients and major clinical-pathological features.
Clinico-pathological features | Metastatic disease | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pt. code | Age | Time between BC diagnosis and CTC collection (months) | BC stage at diagnosis | Histological features of the primary tumor | Bone | Lung | Liver | Brain | Other sites | # of metastases (≤5; >5) | |||
A) Treatment-naїve patients | |||||||||||||
274 | 41 | 2 | IV | Ductal, G3, Ki67 70% ER-, PgR-, Her2neu− | + | − | + | − | + | >5 | |||
337 | 49 | 11 | IV | Ductal, G3, Ki67 54% ER+, PgR+, Her2neu− | − | + | − | − | + | >5 | |||
372 | 53 | 1 | IV | Lobular, G NA, Ki67 15% ER+, PgR−, Her2neu− | + | − | − | − | − | >5 | |||
382 | 73 | 2 | IV | Ductal, G3, Ki67 40% ER+, PgR+, Her2neu− | + | − | − | − | − | >5 | |||
392 | 77 | 1 | IV | Ductal, G2, Ki67 18% ER+, PgR+, Her2neu− | − | + | − | − | + | >5 | |||
407 | 47 | 2 | IV | Ductal, G2, Ki67 27% ER+, PgR+, Her2neu+ | + | + | − | − | − | >5 | |||
454 | 65 | 120 | III | Lobular, G3, Ki67 8% ER+, PgR+, Her2neu− | − | + | − | − | − | ≤5 | |||
Clinico-pathological features | Metastatic disease | ||||||||||||
Pt code | Age | Time between BC diagnosis and CTC collection (months) | BC stage at diagnosis | Histological features of the primary tumor | N. of treatment lines for metastatic disease | Previous treatment | Time since last systemic treatment | Bone | Lung | Liver | Brain | Other sites | # of metastases (≤5; >5) |
B) Pre-treated patients | |||||||||||||
123 | 54 | 12 | III | Ductal, G3, Ki67 50% ER+, PgR+, Her2neu− | 0 | HT (adjuvant) | 21 days | − | − | − | − | + | ≤5 |
242 | 44 | 132 | III | Ductal, G3, Ki67 14% ER+, PgR−, Her2neu− | 8 | CHT, HT | 25 days | + | + | − | − | + | >5 |
253 | 69 | 260 | I | Ductal, G1, Ki67 NA ER+, PgR+, Her2neu+ | 6 | CHT, HT, TT | 60 days | + | + | + | − | + | >5 |
279 | 49 | 23 | IV | Ductal, G NA, Ki67 32% ER+, PgR+, Her2neu− | 1 | HT | 21 days | + | − | − | − | − | >5 |
335 | 69 | 130 | II | Ductal, G2, Ki67 36% ER+, PgR+, Her2neu− | 2 | CHT, HT | 22 days | + | + | − | − | + | >5 |
371 | 56 | 180 | III | Ductal, G2, Ki67 16% ER+, PgR+, Her2neu− | 1 | CHT, HT | 38 days | − | − | + | − | − | ≤5 |
399 | 61 | 36 | III | Ductal, G3, Ki67 45% ER+, PgR+, Her2neu+ | 0 | CHT, HT, TT (adjuvant) | 28 days | − | − | − | + | − | ≤5 |
431 | 52 | 132 | III | Ductal, G2, Ki67 22% ER+, PgR+, Her2neu− | 0 | HT (adjuvant) | 6 years | + | − | − | + | − | >5 |
458 | 55 | 60 | III | Ductal, G3, Ki67 70% ER−, PgR−, Her2neu− | 1 | CHT | 7 months | + | + | + | − | + | >5 |
471 | 67 | 58 | III | Ductal, G3, Ki67 25% ER+, PgR+, Her2neu− | 0 | CHT, HT (adjuvant) | 21 days | − | − | − | − | + | >5 |
